Connect with us
[bsa_pro_ad_space id=12]

Brownstone Institute

Musk Declines to Save Twitter from Itself

Published

12 minute read

From the Brownstone Institute

The question is finally settled: Elon Musk has declined to buy Twitter. His initial offer of $44 billion was contingent on truth and transparency of the company’s corporate filings.

It’s no different from the contract you put on a house: the inspections still remain. If the foundation is cracked – or, worse, if the owners block the inspectors from even looking into the question – the deal is off.

The letter from Musk’s attorney makes it absolutely and painfully clear that Twitter did not cooperate.

“Twitter has not provided information that Mr. Musk has requested for nearly two months notwithstanding his repeated, detailed clarifications intended to simplify Twitter’s identification, collection, and disclosure of the most relevant information sought in Mr. Musk’s original requests.”

There are many issues here but the central one concerns the mDAU or monetizable daily active users. They claim 217 million, nearly half of whom log on daily, and only 5% of whom are bots. To manage them, Twitter has 7,500 employees who earn an average salary of $121,000 per year.

Honestly, if you claim to have a magic machine that displays random thoughts from anyone that somehow converts people’s passing attention into profit – and employ that many people at such high salaries who make it all happen – you had better be sure that you can generate credible numbers to prove it.

Twitter never did.

Maybe the foundation is cracked or maybe it is not. But when the owners don’t let you verify, there is a reason to walk away.

It would be nice to know Musk’s real thoughts. I suspect that Elon looked more closely at this vaunted ruling-class time waster and found vast puffery, low profitability, wildly inflated numbers concerning usage, and a vicious and expensive staff that hates his guts, while opposing free speech and the values of most regular American people.

Why would he bother?

It’s all strange timing for the company suddenly to announce massive cuts in its payroll, starting with the team dedicated to job recruitment. That would appear to mean the HR staff, which is undoubtedly huge, but a net drain on any company seeking profitability. Maybe this move was made in response to Musk — let’s clean house before the new owner takes over — or maybe it was made necessary by poor financials.

In either case, Musk might have come to believe that the entire company is a dog he doesn’t want to adopt.

Meanwhile, Twitter seems to have settled a lawsuit with Alex Berenson, an early Covid-policy critic who was later banned for posting…facts. The terms of the settlement are secret but they did result in his reinstatement. The same day, however, Twitter went on an aggressive purge of other accounts that dared to post basic facts particularly about covid and vaccine effectiveness.

Again, why would Musk even bother? There are plenty of other projects out there that merit his attention that could actually make money. Plus, he will be spared the ultimate annoyance of dealing with thousands of entitled and overpaid staffers who have drunk deeply from the woke ideological wells of poststructuralist Ivy-League theorizing.

He might dream of firing 90 percent of them — I dream the same — but what does that achieve?

What is the future of this company and others like them that have lived off enthusiasm, cheap credit, and their influencer status, while obscuring the underlying data that matters most? We know that Facebook, YouTube, and many others have already been caught making wild exaggerations about their mDAUs. It makes sense that Twitter is guilty of the same.

What does this mean for the company? We are seeing the unfolding of a very strange inflationary recession that combines low unemployment, declining purchasing power, falling demand for goods and services, low investor confidence, plus a growing financial squeeze that is raising serious questions about whether the basic economic model of high-profile companies like Twitter is sustainable.

George Gilder has foreseen the end of Google, one company the name of which he deploys as a stand-in for a slew of high fliers that dominate Big Tech today. Precisely how they would bite the dust has always been a question. It would be the height of irony to see them all die the death from the very forces that gave them such high profitability in 2020 and 2021: the pandemic response that conscripted their user base from the real world into the laptop life.

And with that comes a more fundamental question: just how vulnerable is this overclass to being euthanized by economic fundamentals?

For example, with the managerial class trying to get everyone back at the office, the overclass of lazy and overpaid staffers is resisting with all the ferocity one would expect from such an entitled proletariat. They simply won’t come back. They prefer the pajama life. It’s more comfortable. It’s also safer because by not showing up to the office, one can more easily hide from managerial oversight.

Right now office occupancy in major cities is at a mere 45% of what it was before the pandemic response. To be sure, many of these people have tried coming back. They fight the traffic. They ride the dangerous subways. They pay a high price for gas. Then they pay to park. Then eat bad food for lunch. And what do they do at the office? The same exact thing they would otherwise be doing at home. They Slack back and forth to other employees.

Doesn’t matter if the interlocutor is 5 feet away or 500 miles away. It’s all the same anyway.

The main reason for coming back to the office is to socialize with fellow employees. But that’s not actually doing work, is it? So that’s a problem. The great myth that having everyone hang out together in fishbowl rooms is going to lead to some kind of synergistic brainstorming has been exposed as another lie promoted by bogus management books one picks up in the airport.

Therefore, employees are coming up with any excuse to stay away. The best one — “I’ve been exposed to Covid so I’m in quarantine” — is getting stale. The high price of gasoline might be next on the list. Regardless, getting people back to the office seems ill-fated, which raises serious questions about what happens to these skyscrapers designed for a pre-2020 world?

We talk these days a lot about the labor shortage and the low unemployment rate. Can we get a bit of honesty here? The shortages are for jobs that many people don’t want. They are in the service industries, hospitality, the physical world, the work that actually requires work and real skills. When you are waving a fancy degree and believe that six figures is your birthright, you won’t take these jobs. That’s why there’s a shortage of workers.

In other words, we need people to fix cars, deliver goods from ports to stores, flip the rooms in hotels, make the omelets, and put up drywall in new houses. Those require skills and actually moving one’s body, which is anathema to the under-40 demographic that studied anthropology and the history of social oppression of everyone during the four-year, debt-financed vacation we call college.

Where there is a surplus is in the puffed-up sector of bullcorn jobs that require about 20 total minutes of engaged time per day. Those are the jobs that everyone wants, but how sustainable are they really during an inflationary recession?

Elon seems to get this. His companies do real things, not fake things. He probably intuits that most of these companies need massive restructuring, both in personnel and in world outlook.

A prediction: there are hard times ahead for the corporate laptoppers as these companies are forced either to become profitable or go bankrupt. And this will lead to a massive crisis and demoralization of an entire generation that has been taught that anyone with the right credentials and connections can get rich forever without doing a lick of real work.

Decades of debt financing have created a spoiled overclass in America that has been taught to hate capitalism and also believe they and their friends can forever earn a high-income stream off the fruits of that system. There could be a rude awakening and it could come sooner rather than later. They wanted a great reset and they are going to get it good and hard.

Now Twitter faces a serious problem. Who is the next buyer and why would this party be any less scrupulous? Also maybe investors should also be a bit more critically minded too.

Author

  • Jeffrey A. Tucker is Founder and President of the Brownstone Institute and the author of many thousands of articles in the scholarly and popular press and ten books in 5 languages, most recently Liberty or Lockdown. He is also the editor of The Best of Mises. He writes a daily column on economics at The Epoch Times, and speaks widely on topics of economics, technology, social philosophy, and culture.

After 15 years as a TV reporter with Global and CBC and as news director of RDTV in Red Deer, Duane set out on his own 2008 as a visual storyteller. During this period, he became fascinated with a burgeoning online world and how it could better serve local communities. This fascination led to Todayville, launched in 2016.

Follow Author

Brownstone Institute

FDA Exposed: Hundreds of Drugs Approved without Proof They Work

Published on

From the Brownstone Institute

By Maryanne Demasi

The US Food and Drug Administration (FDA) has approved hundreds of drugs without proof that they work—and in some cases, despite evidence that they cause harm.

That’s the finding of a blistering two-year investigation by medical journalists Jeanne Lenzer and Shannon Brownleepublished by The Lever.

Reviewing more than 400 drug approvals between 2013 and 2022, the authors found the agency repeatedly ignored its own scientific standards.

One expert put it bluntly—the FDA’s threshold for evidence “can’t go any lower because it’s already in the dirt.”

A System Built on Weak Evidence

The findings were damning—73% of drugs approved by the FDA during the study period failed to meet all four basic criteria for demonstrating “substantial evidence” of effectiveness.

Those four criteria—presence of a control group, replication in two well-conducted trials, blinding of participants and investigators, and the use of clinical endpoints like symptom relief or extended survival—are supposed to be the bedrock of drug evaluation.

Yet only 28% of drugs met all four criteria—40 drugs met none.

These aren’t obscure technicalities—they are the most basic safeguards to protect patients from ineffective or dangerous treatments.

But under political and industry pressure, the FDA has increasingly abandoned them in favour of speed and so-called “regulatory flexibility.”

Since the early 1990s, the agency has relied heavily on expedited pathways that fast-track drugs to market.

In theory, this balances urgency with scientific rigour. In practice, it has flipped the process. Companies can now get drugs approved before proving that they work, with the promise of follow-up trials later.

But, as Lenzer and Brownlee revealed, “Nearly half of the required follow-up studies are never completed—and those that are often fail to show the drugs work, even while they remain on the market.”

“This represents a seismic shift in FDA regulation that has been quietly accomplished with virtually no awareness by doctors or the public,” they added.

More than half the approvals examined relied on preliminary data—not solid evidence that patients lived longer, felt better, or functioned more effectively.

And even when follow-up studies are conducted, many rely on the same flawed surrogate measures rather than hard clinical outcomes.

The result: a regulatory system where the FDA no longer acts as a gatekeeper—but as a passive observer.

Cancer Drugs: High Stakes, Low Standards

Nowhere is this failure more visible than in oncology.

Only 3 out of 123 cancer drugs approved between 2013 and 2022 met all four of the FDA’s basic scientific standards.

Most—81%—were approved based on surrogate endpoints like tumour shrinkage, without any evidence that they improved survival or quality of life.

Take Copiktra, for example—a drug approved in 2018 for blood cancers. The FDA gave it the green light based on improved “progression-free survival,” a measure of how long a tumour stays stable.

But a review of post-marketing data showed that patients taking Copiktra died 11 months earlier than those on a comparator drug.

It took six years after those studies showed the drug reduced patients’ survival for the FDA to warn the public that Copiktra should not be used as a first- or second-line treatment for certain types of leukaemia and lymphoma, citing “an increased risk of treatment-related mortality.”

Elmiron: Ineffective, Dangerous—And Still on the Market

Another striking case is Elmiron, approved in 1996 for interstitial cystitis—a painful bladder condition.

The FDA authorized it based on “close to zero data,” on the condition that the company conduct a follow-up study to determine whether it actually worked.

That study wasn’t completed for 18 years—and when it was, it showed Elmiron was no better than placebo.

In the meantime, hundreds of patients suffered vision loss or blindness. Others were hospitalized with colitis. Some died.

Yet Elmiron is still on the market today. Doctors continue to prescribe it.

“Hundreds of thousands of patients have been exposed to the drug, and the American Urological Association lists it as the only FDA-approved medication for interstitial cystitis,” Lenzer and Brownlee reported.

“Dangling Approvals” and Regulatory Paralysis

The FDA even has a term—”dangling approvals”—for drugs that remain on the market despite failed or missing follow-up trials.

One notorious case is Avastin, approved in 2008 for metastatic breast cancer.

It was fast-tracked, again, based on ‘progression-free survival.’ But after five clinical trials showed no improvement in overall survival—and raised serious safety concerns—the FDA moved to revoke its approval for metastatic breast cancer.

The backlash was intense.

Drug companies and patient advocacy groups launched a campaign to keep Avastin on the market. FDA staff received violent threats. Police were posted outside the agency’s building.

The fallout was so severe that for more than two decades afterwards, the FDA did not initiate another involuntary drug withdrawal in the face of industry opposition.

Billions Wasted, Thousands Harmed

Between 2018 and 2021, US taxpayers—through Medicare and Medicaid—paid $18 billion for drugs approved under the condition that follow-up studies would be conducted. Many never were.

The cost in lives is even higher.

A 2015 study found that 86% of cancer drugs approved between 2008 and 2012 based on surrogate outcomes showed no evidence that they helped patients live longer.

An estimated 128,000 Americans die each year from the effects of properly prescribed medications—excluding opioid overdoses. That’s more than all deaths from illegal drugs combined.

A 2024 analysis by Danish physician Peter Gøtzsche found that adverse effects from prescription medicines now rank among the top three causes of death globally.

Doctors Misled by the Drug Labels

Despite the scale of the problem, most patients—and most doctors—have no idea.

A 2016 survey published in JAMA asked practising physicians a simple question—what does FDA approval actually mean?

Only 6% got it right.

The rest assumed that it meant the drug had shown clear, clinically meaningful benefits—such as helping patients live longer or feel better—and that the data was statistically sound.

But the FDA requires none of that.

Drugs can be approved based on a single small study, a surrogate endpoint, or marginal statistical findings. Labels are often based on limited data, yet many doctors take them at face value.

Harvard researcher Aaron Kesselheim, who led the survey, said the results were “disappointing, but not entirely surprising,” noting that few doctors are taught about how the FDA’s regulatory process actually works.

Instead, physicians often rely on labels, marketing, or assumptions—believing that if the FDA has authorized a drug, it must be both safe and effective.

But as The Lever investigation shows, that is not a safe assumption.

And without that knowledge, even well-meaning physicians may prescribe drugs that do little good—and cause real harm.

Who Is the FDA Working for?

In interviews with more than 100 experts, patients, and former regulators, Lenzer and Brownlee found widespread concern that the FDA has lost its way.

Many pointed to the agency’s dependence on industry money. A BMJ investigation in 2022 found that user fees now fund two-thirds of the FDA’s drug review budget—raising serious questions about independence.

Yale physician and regulatory expert Reshma Ramachandran said the system is in urgent need of reform.

“We need an agency that’s independent from the industry it regulates and that uses high-quality science to assess the safety and efficacy of new drugs,” she told The Lever. “Without that, we might as well go back to the days of snake oil and patent medicines.”

For now, patients remain unwitting participants in a vast, unspoken experiment—taking drugs that may never have been properly tested, trusting a regulator that too often fails to protect them.

And as Lenzer and Brownlee conclude, that trust is increasingly misplaced.

Republished from the author’s Substack

 

Author

Maryanne Demasi, 2023 Brownstone Fellow, is an investigative medical reporter with a PhD in rheumatology, who writes for online media and top tiered medical journals. For over a decade, she produced TV documentaries for the Australian Broadcasting Corporation (ABC) and has worked as a speechwriter and political advisor for the South Australian Science Minister.

Continue Reading

Brownstone Institute

Anthony Fauci Gets Demolished by White House in New Covid Update

Published on

From the Brownstone Institute

By  Ian Miller 

Anthony Fauci must be furious.

He spent years proudly being the public face of the country’s response to the Covid-19 pandemic. He did, however, flip-flop on almost every major issue, seamlessly managing to shift his guidance based on current political whims and an enormous desire to coerce behavior.

Nowhere was this more obvious than his dictates on masks. If you recall, in February 2020, Fauci infamously stated on 60 Minutes that masks didn’t work. That they didn’t provide the protection people thought they did, there were gaps in the fit, and wearing masks could actually make things worse by encouraging wearers to touch their face.

Just a few months later, he did a 180, then backtracked by making up a post-hoc justification for his initial remarks. Laughably, Fauci said that he recommended against masks to protect supply for healthcare workers, as if hospitals would ever buy cloth masks on Amazon like the general public.

Later in interviews, he guaranteed that cities or states that listened to his advice would fare better than those that didn’t. Masks would limit Covid transmission so effectively, he believed, that it would be immediately obvious which states had mandates and which didn’t. It was obvious, but not in the way he expected.

And now, finally, after years of being proven wrong, the White House has officially and thoroughly rebuked Fauci in every conceivable way.

White House Covid Page Points Out Fauci’s Duplicitous Guidance

A new White House official page points out, in detail, exactly where Fauci and the public health expert class went wrong on Covid.

It starts by laying out the case for the lab-leak origin of the coronavirus, with explanations of how Fauci and his partners misled the public by obscuring information and evidence. How they used the “FOIA lady” to hide emails, used private communications to avoid scrutiny, and downplayed the conduct of EcoHealth Alliance because they helped fund it.

They roast the World Health Organization for caving to China and attempting to broaden its powers in the aftermath of “abject failure.”

“The WHO’s response to the COVID-19 pandemic was an abject failure because it caved to pressure from the Chinese Communist Party and placed China’s political interests ahead of its international duties. Further, the WHO’s newest effort to solve the problems exacerbated by the COVID-19 pandemic — via a “Pandemic Treaty” — may harm the United States,” the site reads.

Social distancing is criticized, correctly pointing out that Fauci testified that there was no scientific data or evidence to support their specific recommendations.

“The ‘6 feet apart’ social distancing recommendation — which shut down schools and small business across the country — was arbitrary and not based on science. During closed door testimony, Dr. Fauci testified that the guidance ‘sort of just appeared.’”

There’s another section demolishing the extended lockdowns that came into effect in blue states like California, Illinois, and New York. Even the initial lockdown, the “15 Days to Slow the Spread,” was a poorly reasoned policy that had no chance of working; extended closures were immensely harmful with no demonstrable benefit.

“Prolonged lockdowns caused immeasurable harm to not only the American economy, but also to the mental and physical health of Americans, with a particularly negative effect on younger citizens. Rather than prioritizing the protection of the most vulnerable populations, federal and state government policies forced millions of Americans to forgo crucial elements of a healthy and financially sound life,” it says.

Then there’s the good stuff: mask mandates. While there’s plenty more detail that could be added, it’s immensely rewarding to see, finally, the truth on an official White House website. Masks don’t work. There’s no evidence supporting mandates, and public health, especially Fauci, flip-flopped without supporting data.

“There was no conclusive evidence that masks effectively protected Americans from COVID-19. Public health officials flipped-flopped on the efficacy of masks without providing Americans scientific data — causing a massive uptick in public distrust.”

This is inarguably true. There were no new studies or data justifying the flip-flop, just wishful thinking and guessing based on results in Asia. It was an inexcusable, world-changing policy that had no basis in evidence, but was treated as equivalent to gospel truth by a willing media and left-wing politicians.

Over time, the CDC and Fauci relied on ridiculous “studies” that were quickly debunked, anecdotes, and ever-shifting goal posts. Wear one cloth mask turned to wear a surgical mask. That turned into “wear two masks,” then wear an N95, then wear two N95s.

All the while ignoring that jurisdictions that tried “high-quality” mask mandates also failed in spectacular fashion.

And that the only high-quality evidence review on masking confirmed no masks worked, even N95s, to prevent Covid transmission, as well as hearing that the CDC knew masks didn’t work anyway.

The website ends with a complete and thorough rebuke of the public health establishment and the Biden administration’s disastrous efforts to censor those who disagreed.

“Public health officials often mislead the American people through conflicting messaging, knee-jerk reactions, and a lack of transparency. Most egregiously, the federal government demonized alternative treatments and disfavored narratives, such as the lab-leak theory, in a shameful effort to coerce and control the American people’s health decisions.

When those efforts failed, the Biden Administration resorted to ‘outright censorship—coercing and colluding with the world’s largest social media companies to censor all COVID-19-related dissent.’”

About time these truths are acknowledged in a public, authoritative manner. Masks don’t work. Lockdowns don’t work. Fauci lied and helped cover up damning evidence.

If only this website had been available years ago.

Though, of course, knowing the media’s political beliefs, they’d have ignored it then, too.

Republished from the author’s Substack

Author

Ian Miller is the author of “Unmasked: The Global Failure of COVID Mask Mandates.” His work has been featured on national television broadcasts, national and international news publications and referenced in multiple best selling books covering the pandemic. He writes a Substack newsletter, also titled “Unmasked.”

Continue Reading

Trending

X